FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2158-2159 November 16, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

To the Editor: Atazanavir sulfate, a protease inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV type 1 (HIV-1) infection.¹ Among the antiretroviral agents that are currently in use, only indinavir is known to cause kidney stones.² We describe a patient who had hydronephrosis and a ureteral stone composed mainly of atazanavir metabolites.

A 44-year-old man with HIV infection presented with abdominal pain, chills, nausea and vomiting, and a decreased oral intake of fluids. His CD4 count was 70 cells per cubic millimeter, and his HIV-1 RNA level was less than 75 copies per milliliter. . . . [Full Text of this Article]

This article has been cited by other articles:

• D'Ythurbide, G., Goujard, C., Mechai, F., Blanc, A., Charpentier, B., Snanoudj, R. (2007). Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol Dial Transplant 22: 3656-3659 [Full Text]